Live Breaking News & Updates on Patients With Advanced Non Small Cell Lung Cancer

Stay updated with breaking news from Patients with advanced non small cell lung cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%. ....

Boca Raton , United States , Edgardos Santos , Ashling Wahner , Florida Atlantic University In Boca Raton , Florida Society Of Clinical Oncology Membership Committee , Regeneron Pharmaceuticals , Live On Air , Florida Atlantic University , Florida Society , Clinical Oncology Membership , Onclive On Air , Apple Podcasts , Google Podcasts , Amazon Music , Empower Lung 1 Trial , Empower Lung 3 Trial , Florida Society Of Clinical Oncology , Cemiplimab Plus Chemotherapy , Patients With Advanced Non Small Cell Lung Cancer ,

Long-Term Survival Benefit With PD-1 Monotherapy Correlated With High PD-L1 Expression in Advanced NSCLC

Biagio Ricciuti, MD, discusses the need to improve the identification of patients with advanced non–small cell lung cancer that benefit most from immune checkpoint inhibition. ....

Dana Farber Cancer Institute , United States , Biagio Ricciuti , Department Of Medicine At Dana Farber Cancer Institute , International Association , Lung Cancer , Patients With Advanced Non Small Cell Lung Cancer ,

Dr Goto on Datopotamab Deruxtecan Plus Pembrolizumab and Chemotherapy in Advanced NSCLC

Yasushi Goto, MD, discusses primary efficacy findings from the phase 1 TROPION-Lung02 trial of datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy in patients with advanced non–small cell lung cancer. ....

National Cancer Center Hospital , Datopotamab Deruxtecan Plus Pembrolizumab , Yasushi Goto , Tropion Lung02 Trial , Patients With Advanced Non Small Cell Lung Cancer ,

THIO Followed By Cemiplimab Displays Safety, Tolerability in Advanced NSCLC

The sequential combination of THIO plus cemiplimab did not lead to any dose-limiting toxicities or significant treatment-related adverse effects in patients with advanced non–small cell lung cancer. ....

Mihail Obrocea , Thio Plus Cemiplimab , Patients With Advanced Non Small Cell Lung Cancer , Thio 101 Trial , Maia Biotechnology , Vlad Vitoc ,